Company’s latest innovation is the first in the industry to offer full intrinsic enteric protection, precluding the need for functional coatings

Morristown, N.J., October 26, 2015 – Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions to the healthcare industry, today announced the global commercial launch of its enTRinsic™ drug delivery technology platform. This first-of-its-kind innovation provides full enteric protection and targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract, without the need for functional coatings.

“Capsugel’s enTRinsic drug delivery technology is the result of our continued commitment to innovate for our customers,” said Amit Patel, President, Capsugel Dosage Form Solutions. “For years the industry has been searching for a fully enteric dosage form that doesn’t require functional coatings. By leveraging Capsugel’s unique combination of formulation, polymer chemistry and manufacturing expertise, we have developed a novel solution for enteric protection and the targeted delivery of a wide range of sensitive molecules.”

Capsugel’s breakthrough technology enables oral delivery of a variety of compounds – including vaccines, proteins and peptides – using pharmaceutically approved enteric polymers. The technology is now globally available for customer projects following the successful completion of an 18-month lead-user customer-collaboration program that included feasibility studies with new and existing pharmaceutical products.

“Our lead-user program confirmed the enteric performance of our enTRinsic technology in multiple applications, as well as the viability of the formulation and manufacture of finished drug product at scale,” said Keith Hutchison, Ph.D., Senior Vice President, Research and Development, Capsugel. “We are now excited to move beyond the lead-user program and work with additional customers, while continuing to broaden the application of the technology to encompass gastric resistance, full enteric protection, and varied GI site targeting for an increasingly diverse range of APIs.”

Capsugel’s enTRinsic technology further expands the company’s range of modified and targeted release solutions, as well as the company’s biotherapeutic formulation offering. Customers can access the technology platform through a services agreement at Capsugel’s locations in Ploërmel, France, and Bend, Ore. This unique offering can be tailored to specific customer projects and combined with other technologies, as warranted, to meet various target product profiles and commercial objectives.    

The enTRinsic drug delivery technology will be featured in a presentation by the project’s lead scientist, Hassan Benameur, Ph.D., Senior Director, Pharmaceutical Sciences, Capsugel, at the AAPS Annual Meeting & Exposition 2015 in Orlando, Fla. The presentation, “Enteric Capsule Drug Delivery Technology – Achieving Full Protection without Coatings,” will take place October 26, 2015, from 12:00-12:45 p.m.

ABOUT CAPSUGEL
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business offers customers the broadest portfolio of gelatin, vegetarian, and other specialized capsule technologies. Capsugel’s Dosage Form Solutions business utilizes an array of proprietary technologies and specialized manufacturing capabilities to solve customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. The company's fast-to-clinic program streamlines product development from pre-formulation through clinical and commercial supply for finished dosage forms. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit www.capsugel.com.